Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Other Operating Expenses: 2009-2024

Historic Other Operating Expenses for Vanda Pharmaceuticals (VNDA) over the last 16 years, with Dec 2024 value amounting to $17.7 million.

  • Vanda Pharmaceuticals' Other Operating Expenses rose 7.81% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.7 million, marking a year-over-year decrease of 0.38%. This contributed to the annual value of $17.7 million for FY2024, which is 10.78% up from last year.
  • Latest data reveals that Vanda Pharmaceuticals reported Other Operating Expenses of $17.7 million as of FY2024, which was up 10.78% from $16.0 million recorded in FY2023.
  • Vanda Pharmaceuticals' 5-year Other Operating Expenses high stood at $25.7 million for FY2021, and its period low was $16.0 million during FY2023.
  • Its 3-year average for Other Operating Expenses is $19.4 million, with a median of $17.7 million in 2024.
  • As far as peak fluctuations go, Vanda Pharmaceuticals' Other Operating Expenses plummeted by 35.05% in 2023, and later climbed by 10.78% in 2024.
  • Over the past 5 years, Vanda Pharmaceuticals' Other Operating Expenses (Yearly) stood at $23.4 million in 2020, then increased by 9.66% to $25.7 million in 2021, then declined by 4.38% to $24.6 million in 2022, then crashed by 35.05% to $16.0 million in 2023, then increased by 10.78% to $17.7 million in 2024.